OSOBENNOSTI POKAZATELEY UL'TRASONOMETRII ZhENSKOGO NASELENIYa GORODA ChELYaBINSKA

Characteristic feature of ultrasonic densitometry have been investigated in women,s population of Chelyabinsk (n=200) from 25 to 65 years old. We used domestically produced Echoosteometr-02. A basis of a body of the lower jaw became a new area for ultrasonic densitometry. We can recommend a lower jaw as a new area for ultrasonic densitometry taking into account high pithiness of data in a combination with simplicity of research. Traditional localizations have been also applied: proximal phalanges of the hand, patella, tibia diaphysis and calcaneus bones of the right and left sides. We have established a "peak" values of a speed of the ultrasound wave for the given bones. Also we have found that a tubular bones and a large spongy bone - a lower jaw - possess the highest speed of an ultrasound wave, and the speed was mach less in a small spongy bones, that is caused by their anatomic structure. Ultrasound densitometry parameters of the peripheral skeleton start to reduce from 40-50 years behind exception patella - from 55 years. The lowest values were in group of women of 60-65 years. The rates of ultrasonic densitometry received by us are possible to use for women population of Chelyabinsk

Experience of managing menopausal symptoms and quality of sleep with melatonin

Melatonin is one of the most underestimated agents of the endocrine system. While remaining undeservedly in the shadow of clinical science, it adjusts the body to the systemic changes of the external and internal environment. The periods of perimenopause and menopause are characterized by high levels of stress and reduced quality of life. In recent years, there is a growing understanding that melatonin as adaptogenic hormone supports the female body in this particularly vulnerable period of life. We assessed secretion of melatonin in women with climacteric syndrome (CS) and the effect of melatonin therapy on menopausal symptoms and quality of sleep. The study involved 31 women (mean age 53.5 ± 4,1 years) with mild CS (average age of menopause 52 ± 3 years). Melatonin secretion was evaluated by the concentration of its metabolite (urinary 6-hydroxy-melatonin-sulfate) using enzyme immunoassay. All patients received melatonin 3 mg/day orally at bedtime for 3 months. The results of the treatment were clinically assessed using the modified menopausal index (MMI) and the Pittsburgh Sleep Quality Index (PSQI). We found that baseline 6-hydroxy-melatonin-sulfate levels were very low in the evening urine: 1.88 ng/ml (1.08 to 5.34); at night and in the early morning they moderately increased (up to 6.36 ng/ml [from 2,34 to 16,04] and 25.71 ng/ml [15.51 to 32.03], respectively). After 1 month of treatment, MMI in the subjects decreased from 24,9 ± 8,1 points to 16,6 ± 8,8 (P = 0.013) and further to 13,2 ± 6,3 points after 3 months (P = 0.001). The MMI demonstrated a significant decrease of neuro-vegetative symptoms. The median PSQI decreased from 9 to 2 points (p = 0,027). Our findings suggest that melatonin is able to inhibit mild CS and the associated sleep disturbances